Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05424757 · ClinicalTrials.gov registry record
Polyethylene Glycol Safety in Children
A clinical trial, sponsored by Children's Hospital of Philadelphia.
- Completed
- Registry status
- 158
- Enrollment target
NCT05424757: Completed study, sponsored by Children's Hospital of Philadelphia.
NCT05424757 is a clinical trial that has completed, run by Children's Hospital of Philadelphia. The registered enrollment target is 158 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05424757 has completed, sponsored by Children's Hospital of Philadelphia.
- COMPLETED
- Registry status
- 158 participants
- Enrollment target
Study Summary
The primary objective is to measure levels of selected PEG 3350 components and metabolites in the blood and urine of children who are already taking PEG 3350 compared to children who are not taking PEG 3350. Changes to medical therapy are not recommended as part of this study.
Primary Outcome
Plasma levels of selected PEG 3350 related molecules will be measured by mass spectrometry using validated assays.
Interventions
- DRUG PEG 3350
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2022-09-30 |
| Est. Completion | 2025-08-09 |
What the finished NCT05424757 record still lists
NCT05424757 is an observational study that tracks outcomes without assigning an intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which PEG 3350 is the first listed.
NCT05424757 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05424757 about?
NCT05424757 is a clinical study titled "Polyethylene Glycol Safety in Children". The primary objective is to measure levels of selected PEG 3350 components and metabolites in the blood and urine of children who are already taking PEG 3350 compared to children who are not taking PEG 3350. Changes to medical therapy are not recommended as part of this study.
What is the current status of trial NCT05424757?
This trial is currently completed. The enrollment target is 158 participants. The study started on 2022-09-30. Estimated completion is 2025-08-09.
What interventions are being tested in trial NCT05424757?
The interventions under investigation include: PEG 3350 (DRUG).
Who is sponsoring clinical trial NCT05424757?
This trial is sponsored by Children's Hospital of Philadelphia, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486833 · 158 participants · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- NCT04697966 · 158 participants · NA
Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents
- NCT04969835 · 158 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- NCT05230732 · 158 participants · NA
Neuromodulation of Inflammation and Endothelial Function
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI